Patients with coagulation factor(s) deficiency who use coagulation therapy are susceptible to forming inhibitors against coagulation factor(s). In this survey we detected factor V and VIII inhibitor in ten patients with combined deficiency of factors V and VIII from north east of Iran (Khorassan province). It was revealed in our survey that eight patients had both factor V and factor VIII i...

Clotting factor V has a dual function in coagulation: after activation, procoagulant factor V stimulates the formation of thrombin, whereas anticoagulant factor V acts as a cofactor for activated protein C (APC) in the degradation of factor VIII/VIIIa, thereby reducing thrombin formation. In the present study, we evaluated whether plasma factor V levels, either decreased or increased, are assoc...

Organ transplantation and perfusion studied indicate that the spleen plays an important role in the regulation of plasma levels of factor VIII-von Willebrand's factor (FVIII-vWF). To better understand the mechanisms that regulate the FVIII-vWF increases after infusion of 1-deamino-8-D-arginine vasopressin (DDAVP), we have measured factor VIII coagulant activity (FVIII:C) and antigen (FVIII:CAg)...

We prepared a highly purified and relatively heat stable form of factor VIII which contained 25 units per mL (u/mL) activity using PEG-4000 and developed an effective and new manufacturing process. Heat treatment was performed at 80°C for 72 hrs in the presence of different stabilizers. In our studies, we used different organic solvents as preservatives to maintain factor VIII activity, sin...

objective(s): the purpose of the present study was the immunohistochemical evaluation of vegf and vii factors in dog’s teeth pulp revascularized with mta and propolis. materials and methods: 144 mature and immature two rooted dog’s premolar canals were selected.  pulp necrosis and infection were established after 2 weeks and the disinfection of the canals was done with copious naocl irrigation ...

An immunoadsorbent method has been developed for the direct analysis of normal and variant plasma factor VIII. Using this method, the molecular defect responsible for mild hemophilia A has been identified for a patient whose plasma factor VIII activity is 0.05 unit/ml, even though the factor VIII antigen content is 3.25 units/ml. Although the variant factor VIII has an apparently normal molecul...

Factor VIII procoagulant activity (VIII:C), factor VIII related antigen (VIIIR:AG), and the von Willebrand factor (VIII:WF) were measured in 19 patients with liver disease (8 cases of alcoholic cirrhosis and 11 with acute viral hepatitis). In both groups of patients the levels of VIII:C, VIIIR:AG, and VIIIR:WF were above normal or normal with mean values well above the normal range. VIIR:AG was...

Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...

This report describes a patient without evident underlying disease, in whom an acquired von Willebrand's syndrome was discovered before surgery. Coagulation abnormalities included a borderline bleeding time, a low retention of platelets on glass beads, decreased levels of factor VIII procoagulant activity (VIIIAHF), factor VIII-related antigen (VIIIAg), and ristocetin-induced agglutination cofa...

Precipitating antibodies to factor VlIl/von Willebrand factor can develop in patients with severe homozygouslike von Willebrand’s disease following multiple transfusions with blood derivatives. This study of 4 patients treated with cryoprecipitate for 1 3 different bleeding episodes demonstrates that the occurrence of such antibodies interferes with the management of the disease. The control of...